Canaccord Genuity analyst Kyle Rose reiterated a Buy rating on InMode (NASDAQ:INMD) on Monday, setting a price target of $80, which is approximately 3.36% below the present share price of $82.78.
Rose expects InMode to post earnings per share (EPS) of $0.96 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in InMode, with an average price target of $82.67.
The analysts price targets range from a high of $84 to a low of $80.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $75.19 million and a net profit of $35.44 million. The company's market cap is $3.16 billion.
According to TipRanks.com, Canaccord Genuity analyst Kyle Rose is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.6% and a 58.33% success rate.
InMode Ltd . designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.